The purpose of this study is to compare BI 695502 (the study drug) to Avastin®. Avastin® has been shown to be effective in patients with non-squamous non-small cell lung cancer in association with chemotherapy. BI 695502 is being developed as a proposed biosimilar (biological medicine) to Avastin®, the approved medicine. The purpose of this study is to confirm that BI 695502 works the same way in patients as the approved medicine Avastin®.